BR112015009107A2 - agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo - Google Patents
agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmoInfo
- Publication number
- BR112015009107A2 BR112015009107A2 BR112015009107A BR112015009107A BR112015009107A2 BR 112015009107 A2 BR112015009107 A2 BR 112015009107A2 BR 112015009107 A BR112015009107 A BR 112015009107A BR 112015009107 A BR112015009107 A BR 112015009107A BR 112015009107 A2 BR112015009107 A2 BR 112015009107A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- growth hormone
- receptor agonist
- hormone secretagogue
- Prior art date
Links
- 229940124072 Growth hormone secretagogue receptor agonist Drugs 0.000 title 2
- 150000003839 salts Chemical class 0.000 title 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012234300 | 2012-10-24 | ||
| PCT/JP2013/078743 WO2014065341A1 (ja) | 2012-10-24 | 2013-10-23 | 筋萎縮性側索硬化症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015009107A2 true BR112015009107A2 (pt) | 2017-11-14 |
Family
ID=50544716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015009107A BR112015009107A2 (pt) | 2012-10-24 | 2013-10-23 | agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150265680A1 (https=) |
| EP (1) | EP2913063B1 (https=) |
| JP (1) | JP6262661B2 (https=) |
| KR (3) | KR102499918B1 (https=) |
| CN (2) | CN110354265A (https=) |
| AU (1) | AU2013335678B9 (https=) |
| BR (1) | BR112015009107A2 (https=) |
| CA (1) | CA2889499C (https=) |
| IN (1) | IN2015DN04172A (https=) |
| RU (1) | RU2655811C2 (https=) |
| WO (1) | WO2014065341A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703884PA (en) | 2014-11-12 | 2017-06-29 | Lyric Pharmaceuticals Inc | Treatment of enteral feeding intolerance |
| WO2017083882A1 (en) * | 2015-11-11 | 2017-05-18 | Lyric Pharmaceuticals Inc. | Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs |
| MA54383A (fr) * | 2018-12-06 | 2021-10-13 | Biogen Ma Inc | Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique |
| KR20250107210A (ko) * | 2022-11-03 | 2025-07-11 | 루모스 파마, 인크. | 이부타모렌의 압축형 경구 제형 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668254A (en) | 1990-05-11 | 1997-09-16 | Romano Deghenghi | D-2-alkyl-tryptophan and peptides containing same |
| US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
| US5536716A (en) | 1992-12-11 | 1996-07-16 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| CA2340701C (en) | 1998-08-20 | 2009-05-26 | Sumitomo Pharmaceuticals Co., Ltd. | Oxindole derivatives as growth hormone releasers |
| KR100827973B1 (ko) * | 1999-07-23 | 2008-05-21 | 겐지 간가와 | 신규 펩티드 |
| UA73530C2 (uk) | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
| ATE304373T1 (de) * | 1999-12-28 | 2005-09-15 | Kaken Pharma Co Ltd | Nervenschutzmittel |
| AR029941A1 (es) | 2000-06-13 | 2003-07-23 | Zentaris Gmbh | Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen |
| WO2003084983A1 (en) | 2002-04-11 | 2003-10-16 | Daiichi Suntory Pharma Co., Ltd. | Process for producing modified peptide |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| JP2005239712A (ja) | 2004-01-30 | 2005-09-08 | Kaken Pharmaceut Co Ltd | 神経突起伸展剤 |
| WO2006079077A2 (en) * | 2005-01-20 | 2006-07-27 | Acadia Pharmaceuticals Inc. | Use of diltiazem or analogs thereof as modulators of ghrelin receptor |
| US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
| CA2625341A1 (en) * | 2005-10-18 | 2007-04-26 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis |
| WO2007146046A2 (en) | 2006-06-07 | 2007-12-21 | Genzyme Corporation | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
| JP2008127377A (ja) | 2006-11-24 | 2008-06-05 | Jichi Medical Univ | Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。 |
| KR100946084B1 (ko) | 2008-03-27 | 2010-03-10 | 주식회사 하이닉스반도체 | 반도체 소자의 수직형 트랜지스터 및 그 형성방법 |
| MX2010010495A (es) * | 2008-04-03 | 2010-10-15 | Hoffmann La Roche | Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares. |
-
2013
- 2013-10-23 WO PCT/JP2013/078743 patent/WO2014065341A1/ja not_active Ceased
- 2013-10-23 CN CN201910808882.7A patent/CN110354265A/zh active Pending
- 2013-10-23 JP JP2014543332A patent/JP6262661B2/ja not_active Expired - Fee Related
- 2013-10-23 RU RU2015119472A patent/RU2655811C2/ru active
- 2013-10-23 KR KR1020227012378A patent/KR102499918B1/ko active Active
- 2013-10-23 KR KR1020207026038A patent/KR20200108494A/ko not_active Withdrawn
- 2013-10-23 IN IN4172DEN2015 patent/IN2015DN04172A/en unknown
- 2013-10-23 EP EP13848825.9A patent/EP2913063B1/en active Active
- 2013-10-23 AU AU2013335678A patent/AU2013335678B9/en active Active
- 2013-10-23 CN CN201380066625.1A patent/CN104853778A/zh active Pending
- 2013-10-23 US US14/437,459 patent/US20150265680A1/en not_active Abandoned
- 2013-10-23 KR KR1020157010085A patent/KR20150070180A/ko not_active Ceased
- 2013-10-23 CA CA2889499A patent/CA2889499C/en active Active
- 2013-10-23 BR BR112015009107A patent/BR112015009107A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2014065341A1 (ja) | 2016-09-08 |
| CA2889499A1 (en) | 2014-05-01 |
| RU2015119472A (ru) | 2016-12-20 |
| JP6262661B2 (ja) | 2018-01-17 |
| AU2013335678A1 (en) | 2015-05-21 |
| KR20220051418A (ko) | 2022-04-26 |
| KR20200108494A (ko) | 2020-09-18 |
| RU2655811C2 (ru) | 2018-05-29 |
| CA2889499C (en) | 2019-09-10 |
| AU2013335678B9 (en) | 2024-12-12 |
| WO2014065341A1 (ja) | 2014-05-01 |
| EP2913063A4 (en) | 2016-07-20 |
| AU2013335678B2 (en) | 2017-10-26 |
| CN104853778A (zh) | 2015-08-19 |
| US20150265680A1 (en) | 2015-09-24 |
| CN110354265A (zh) | 2019-10-22 |
| HK1214152A1 (en) | 2016-07-22 |
| KR102499918B1 (ko) | 2023-02-14 |
| KR20150070180A (ko) | 2015-06-24 |
| EP2913063B1 (en) | 2019-09-11 |
| EP2913063A1 (en) | 2015-09-02 |
| IN2015DN04172A (https=) | 2015-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015010314A2 (pt) | composto ou sais farmaceuticamente aceitáveis ou isômeros dos mesmos, composição farmacêutica secretagogo de insulina ou agente hipoglicêmico, agonista do receptor gpr40, e, método para tratar doenças ou distúrbios | |
| CL2014000802A1 (es) | Proceso para la preparacion de estetrol, util para terapia de reemplazo hormonal y la anticoncepcion. | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112015003376A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente | |
| IL233324A (en) | Dimeric compounds as agonist receptor for fgf, process for their preparation and medical use | |
| BR112014003802A2 (pt) | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento | |
| EP2991711A4 (en) | DRUGS CHARGE DEVICE | |
| BR112013017752A2 (pt) | uso de um antagonista do vegf e formulação farmacêutica | |
| MX377410B (es) | Antagonistas de receptores de integrina y sus metodos de uso. | |
| IL244813A0 (en) | A compound with agonistic activity for the somatostatin receptor and its medicinal use | |
| PL3409270T3 (pl) | Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta- adrenergiczny do podawania wziewnego | |
| BR112013016862A2 (pt) | combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson | |
| BR112013010102A2 (pt) | microagulha, arranjo de microagulhas, dispositivo de microagulhas, e, método para administrar um agente medicinal | |
| BR112013030302A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo | |
| BR112014005407A2 (pt) | composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv | |
| CL2015001652A1 (es) | Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor. | |
| BRPI1013988A2 (pt) | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo | |
| BR112014002845A2 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
| ZA201309683B (en) | Neutraling prolactin receptor antibody mat3 and its therapeutic use | |
| GB201312344D0 (en) | Liposomal drug delivery system for bone cements | |
| HRP20191361T1 (hr) | Pripravci ceramidaze terapeutske kiseline i postupci njihove izrade i uporabe | |
| EP2990040A4 (en) | Therapeutic agent for eyeground disease | |
| EP3019130A4 (en) | DRUG-PROLONGED TRANSDERMAL RELEASE KIT USING LIQUID OR SEMI-SOLID COMPOSITIONS AND METHOD OF USING THE SAME | |
| IL227705A0 (en) | Topical antifungal agent, compositions comprising the same and uses thereof | |
| BR112015009107A2 (pt) | agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |